The original disclosure in Japanese was released on Jan. 29, 2016 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2015
FY2016 (April 1, 2015 - March 31, 2016) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): February 10, 2016

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2015 (April 1, 2015 – December 31, 2015)

(1) Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2015		Nine months ended December 31, 2014	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	170,250	2.5	166,054	4.1
Operating income(loss)	10,091	(4.6)	10,580	19.0
Ordinary income(loss)	10,858	(1.0)	10,969	19.2
Net income (loss) attributable to owners of the parent	6,546	9.4	5,984	(43.0)
Net income (loss) per share (Yen)	32.53		29.74	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	4,679	(47.6)	8,932	(61.5)

(2) Financial position

	As of December 31, 2015	As of March 31, 2015
	(Millions of yen)	(Millions of yen)
Total assets	263,167	264,438
Net assets	158,716	158,404
Equity ratio (%)	50.6	49.9
(Reference) Equity	133,134	131,923

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2015	Year ending March 31, 2016	Year ending March 31, 2016 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	10.00		11.00
Annual	10.00		11.00

Notes: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2016 (April 1, 2015 – March 31, 2016)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2016	
	(Millions of yen)	(%)
Net sales	230,000	4.8
Operating income(loss)	11,300	1.8
Ordinary income(loss)	12,000	1.5
Net income (loss) attributable to owners of the parent	6,400	12.2
Net income (loss) per share (Yen)	31.81	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change in specific subsidiaries) : No

(2) Applying of specific accounting treatments of the quarterly consolidated financial statements : No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of December 31, 2015 :	217,699,743
As of March 31, 2015 :	217,699,743

2) Number of treasury stocks at year end

As of December 31, 2015 :	16,475,207
As of March 31, 2015 :	16,474,061

3) Average number of outstanding shares

Nine months ended December 31, 2015 :	201,225,138
Nine months ended December 31, 2014 :	201,228,103

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2015 ---------- 2
(1) Consolidated Financial Results ---------- 2
(2) Consolidated Financial Position ---------- 3
(3) Qualitative Information Regarding Consolidated Forecasts ---------- 3
2 Summary Information (Notes) ---------- 4
Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
3. Consolidated Quarterly Financial Statements ---------- 5
(1) Consolidated Quarterly Balance Sheets ---------- 5
(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ---------- 7
Consolidated Quarterly Statements of Income
(For the Nine Months Ended December 31, 2015 and 2014) ---------- 7
Consolidated Quarterly Statements of Comprehensive Income
(For the Nine Months Ended December 31, 2015 and 2014) ---------- 8
(3) Notes on Consolidated Quarterly Financial Statements ---------- 9
(Notes on Premise of Going Concern) ---------- 9
(Notes on Material Changes in Shareholders' Equity) ---------- 9
(Segment Information) ---------- 9

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2015

(1) Consolidated Financial Results

In the nine months ended December 31, 2015, the Japanese economy maintained a moderate recovery as corporate earnings, primarily among export-related companies, and the hiring and income environment improved.

On the other hand, overseas, while the United States maintained a moderate economic expansion, the uncertainty over the outlook for the global economy remained due in part to such factors as the slowdown in the Chinese economy and the accompanying fall in resource prices.

In this environment, under the Takara Group Medium-Term Management Plan FY2017, the second step in its efforts to realize its long-term Takara Group Vision 2020, the Group strived to conduct steady business activities with the aim of improving domestic business profitability and expanding our overseas business intending to further increase the corporate value of the Group, while at the same time building a well-balanced business structure that can hold up well to business environment changes by accelerating the growth of our Biomedical Business.

As a result, in the nine months ended December 31, 2015, net sales were up 2.5% year on year to ¥170,250 million. Gross profit rose 4.3% year on year to ¥67,901 million. Operating income decreased 4.6% year on year to ¥10,091 million while ordinary income was down 1.0% year on year to ¥10,858 million. Net income attributable to owners of the parent increased 9.4% year on year to ¥6,546 million.

Results by business segment were as follows.

Reporting segments were changed from the first quarter ended June 30, 2015. The year on year comparisons shown below compare figures for the same period of the previous fiscal year that have been reclassified into reporting segments following the change.

[Takara Shuzo Group]

For alcoholic beverages, in the nine months ended December 31, 2015, sales of shochu decreased. However, sales of sake increased, as sparkling sake *Sho-Chiku-Bai Shirakabe-gura Mio* continued to sell well, and, overseas, TAKARA SAKE USA INC. performed strongly. Sales of light-alcohol refreshers also rose as the new *Takara Fruit Juice Zero Sugar Chu-Hi Zero Jitate* was launched in June and sales of *Takara Shochu High Ball* remained robust.

Although sales of other alcoholic beverages such as whiskey and wine also rose, sales of alcoholic beverages overall declined due to the major decrease in shochu sales.

In the Seasonings Business, sales of mirin and cooking sake increased while sales of raw alcohol, etc. and transportation sales also increased.

Moreover, sales in the Japanese Food Wholesale Business in overseas markets increased as FOODEX S.A.S. (France) and COMINPORT DISTRIBUCIÓN S.L. (Spain) continued to perform strongly.

As a result, net sales for the Takara Shuzo Group increased 0.5% year on year to ¥146,859 million. Cost of sales was the same as the same period of the previous fiscal year at ¥91,986 million. As a result, gross profit rose 1.2% year on year to ¥54,872 million. SG&A expenses were up 2.2% year on year to ¥46,787 million due to an increase in sales promotion expenses. Accordingly, the Takara Shuzo Group recorded operating income down 4.2% year on year to ¥8,085 million.

[Takara Bio Group]

Net sales for the nine months ended December 31, 2015 increased 19.7% year on year to ¥20,706 million, which was due in part to the impact of the depreciation in the value of the yen in addition to sales of mainstay research reagents, which outperformed the same period of the previous fiscal year. Cost of sales was up 17.3% year on year to ¥9,199 million in conjunction with the increase in net sales. Consequently, gross profit increased 21.7% year on year to ¥11,507 million. SG&A expenses were up 22.9% year on year to ¥10,062 million due to increases in research and development and personnel expenses. Accordingly, the Takara Bio Group recorded operating income up 14.4% year on year to ¥1,444 million.

[Takara Healthcare]

Net sales for the nine month period ended December 31, 2015 increased 11.9% year on year to ¥1,376 million as sales of *fucoidan*-related products etc. continued to grow. Cost of sales was up 8.9% year on year to ¥650 million in conjunction with the increase in net sales. Consequently, gross profit increased 14.8% year on year to ¥725 million. SG&A expenses were up 13.7% year on year to ¥685 million, mainly due to the increase in advertising expenses. As a result, Takara Healthcare recorded operating income up 35.3% year on year to ¥40 million.

[Other]

Net sales of business segments other than the reported segments decreased 4.5% year on year to ¥4,369 million. Cost of sales fell 4.4% year on year to ¥3,836 million. Consequently, gross profit fell 5.0% year on year to ¥532 million. SG&A expenses were up 0.7% year on year to ¥499 million. As a result, operating income in business segments other than the reported segments was down 48.9% year on year to ¥32 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2014, to December 31, 2014)	Period under Review (from April 1, 2015, to December 31, 2015)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	49,675	45,539	91.7
Sake	19,817	19,848	100.2
Light-alcohol refreshers	20,249	21,263	105.0
Other alcoholic beverages	10,128	10,458	103.3
Alcoholic beverages total	99,870	97,110	97.2
Hon Mirin	11,368	11,933	105.0
Other seasonings	6,969	7,199	103.3
Seasonings total	18,338	19,133	104.3
Raw alcohol, etc.	5,378	5,432	101.0
Transportation	8,671	8,922	102.9
Japanese food wholesales business in overseas markets	12,747	15,164	119.0
Other	1,171	1,096	93.6
Total	146,178	146,859	100.5
Takara Bio Group	17,293	20,706	119.7
Takara Healthcare	1,230	1,376	111.9
Other	4,575	4,369	95.5
Sales not allocated to business segments and intersegment transactions	(3,222)	(3,061)	-
Total	**166,054**	**170,250**	**102.5**

Notes: 1. Amounts include alcohol tax but do not include consumption tax.

2. From the first quarter of this fiscal year, the Company had made changes to reporting segments, and sales results for the first nine months of the previous fiscal year have been prepared and presented in accordance with reporting segments following the changes. See "3. Consolidated Quarterly Financial Statements (4) Notes on Consolidated Quarterly Financial Statements (Segment Information)"for details of changes to reporting segments.

(2) Consolidated Financial Position

Total assets stood at ¥263,167 million as of December 31, 2015, down ¥1,271 million from March 31, 2015. This included a ¥5,123 million increase in current assets from the end of the previous fiscal year to ¥165,776 million. This primarily resulted from an increase of ¥10,023 million in notes and accounts receivable-trade and a ¥5,786 million decrease in securities.

Non-current assets decreased by ¥6,394 million from the end of the previous fiscal year to ¥97,390 million. The main factor was a decrease of ¥4,879 million in investment securities.

Total liabilities amounted to ¥104,450 million as of December 31, 2015, down ¥1,583 million from March 31, 2015. Current liabilities fell ¥1,196 million from the end of the previous fiscal year to ¥53,680 million. This primarily resulted from a decline of ¥5,000 million in the current portion of bonds and a decline of ¥1,407 million in other current liabilities such as accrued consumption taxes and an increase of ¥5,076 million in accrued alcohol tax.

Non-current liabilities declined ¥386 million from the end of the previous fiscal year to ¥50,770 million.

Net assets stood at ¥158,716 million as of December 31, 2015, up ¥312 million from March 31, 2015. The main factor was an increase of ¥4,507 million in retained earnings despite a decrease of ¥1,316 million in capital surplus, a decrease of ¥1,459 million in foreign currency translation adjustment, and a decrease of ¥899 million in non-controlling interests.

(3) Qualitative Information Regarding Consolidated Forecasts

Net sales, operating income and ordinary income fell somewhat below forecasts during the nine months ended December 31, 2015, which was largely due to the slow pace in the domestic alcoholic beverage business. However, net income attributable to the parent company exceeded forecasts. As a result, the full-year forecasts for the fiscal year ending March 31, 2016 are unchanged from the forecasts announced on May 8, 2015.

2. Summary Information (Notes)

Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Accounting Standard for Business Combinations)

The "Revised Accounting Standard for Business Combinations" (ASBJ Statement No. 21 issued on September 13, 2013, hereinafter the "Business Combinations Accounting Standard"), the "Revised Accounting Standard for Consolidated Financial Statements" (ASBJ Statement No. 22, September 13, 2013, hereinafter the "Consolidated Financial Statements Accounting Standard"), and the "Revised Accounting Standard for Business Divestitures" (ASBJ Statement No. 7, September 13, 2013, hereinafter the "Business Divestitures Accounting Standard") have been applied from the first quarter of this fiscal year. As a result, for subsidiaries the Company continues to control, differences arising due to changes in the ownership interest are entered in capital surplus and costs associated with the acquisition of ownership interests are now treated as expenses in the consolidated fiscal year in which they are incurred. In addition, for business combinations that are implemented after the beginning of the first quarter of 2015, revisions to the allocation of the cost of acquisitions as determined by provisional accounting treatment are reflected in the quarterly consolidated financial statements for the quarter in which the business combination took place. Additionally, the Company has changed the method of presenting consolidated quarterly net income and changed "minority interests in consolidated subsidiaries" to non-controlling interests in consolidated subsidiaries." To reflect these changes, the Company has reclassified its quarterly consolidated financial statements for the first nine months of the previous fiscal year and consolidated financial statements for the previous fiscal year.

The Company has applied these standards in accordance with transitional treatment prescribed in Section 58-2(4) of the Business Combinations Accounting Standard, Section 44-5(4) of the Consolidated Financial Statements Accounting Standard, Section 57-4(4) of the Business Divestitures Accounting Standard, and will continue to apply these standards from the beginning of the first quarter of this fiscal year into the future.

As a result of these changes, consolidated operating income, ordinary income and net income before income taxes increased by ¥26 million respectively for the nine months ended December 31, 2015. In addition, capital surplus as of December 31, 2015 decreased by ¥1,316 million.

3. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2015	As of Dec. 31, 2015
Assets		
Current assets		
Cash and deposits	41,296	39,611
Notes and accounts receivable-trade	54,617	64,641
Securities	27,022	21,235
Merchandise and finished goods	28,524	30,829
Work in process	958	1,218
Raw materials and supplies	3,317	3,495
Other	5,148	5,008
Allowance for doubtful accounts	(233)	(264)
Total current assets	160,653	165,776
Noncurrent assets		
Property, plant and equipment	53,085	52,723
Intangible assets		
Goodwill	8,071	7,225
Other	4,286	3,977
Total intangible assets	12,358	11,202
Investments and other assets		
Investment securities	32,900	28,020
Other	5,608	5,612
Allowance for doubtful accounts	(166)	(168)
Total investments and other assets	38,342	33,464
Total noncurrent assets	103,785	97,390
Total assets	264,438	263,167

(Millions of Yen)

	As of Mar. 31, 2015	As of Dec. 31, 2015
Liabilities		
Current liabilities		
Notes and accounts payable-trade	15,680	16,141
Short-term loans payable	5,292	5,357
Current portion of bonds	5,000	-
Accrued alcohol tax	7,615	12,691
Accrued expenses	5,456	5,280
Income taxes payable	2,107	2,397
Provision for sales promotion expenses	1,774	2,082
Other provision	2,255	1,440
Other	9,695	8,287
Total current liabilities	54,877	53,680
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	10,334	10,295
Net defined benefit liability	8,407	8,546
Long-term deposits received	5,622	5,346
Other	6,792	6,581
Total noncurrent liabilities	51,156	50,770
Total liabilities	106,034	104,450
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,196	1,879
Retained earnings	108,647	113,154
Treasury stock	(9,937)	(9,938)
Total shareholders' equity	115,132	118,321
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	9,098	9,042
Deferred gains or losses on hedges	558	137
Foreign currency translation adjustment	7,431	5,971
Remeasurements of defined benefit plans	(297)	(338)
Total accumulated other comprehensive income	16,791	14,813
Noncontrolling interests	26,481	25,581
Total net assets	158,404	158,716
Total liabilities and net assets	264,438	263,167

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Nine Months Ended December 31, 2015 and 2014)

(Millions of Yen)

	FY2015 (Apr. 1, 2014 – Dec. 31, 2014)	FY2016 (Apr. 1, 2015 – Dec. 31, 2015)
Net sales	166,054	170,250
Cost of sales	100,975	102,349
Gross profit	65,078	67,901
Selling, general and administrative expenses	54,497	57,809
Operating income	10,580	10,091
Non-operating income		
Dividends income	414	436
Equity in earnings of affiliates	160	275
Other	382	533
Total non-operating income	957	1,245
Non-operating expenses		
Interest expenses	347	335
Other	220	143
Total non-operating expenses	568	479
Ordinary income	10,969	10,858
Extraordinary income		
Gain on sales of investment securities	249	260
Other	62	67
Total extraordinary income	312	327
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	226	148
Impairment loss	247	-
Other	55	51
Total extraordinary losses	529	199
Income before income taxes and minority interests	10,752	10,986
Income taxes-current	3,578	4,168
Income taxes-deferred	1,009	(122)
Total income taxes	4,588	4,046
Net income	6,163	6,940
Net income attributable to the noncontrolling interest	179	393
Net income attributable to owners of the parent	5,984	6,546

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Nine Months Ended December 31, 2015 and 2014)

(Millions of Yen)

	FY2015 (Apr. 1, 2014 – Dec. 31, 2014)	FY2016 (Apr. 1, 2015 – Dec. 31, 2015)
Net income	6,163	6,940
Other comprehensive income		
Valuation difference on available-for-sale securities	1,602	(56)
Deferred gains or losses on hedges	426	(425)
Foreign currency translation adjustment	776	(1,732)
Remeasurements of defined benefit plans	(138)	(34)
Share of other comprehensive income of associates accounted for using equity method	101	(11)
Total other comprehensive income	2,768	(2,260)
Comprehensive income	8,932	4,679
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	8,602	4,568
Comprehensive income attributable to noncontrolling interest	329	110

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2014, to December 31, 2014)

1. Net sales and Income (Loss) by Reported Segment

<Information for the first nine months of the previous fiscal year prepared in accordance with classifications following changes>

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	145,928	16,708	1,228	163,864	1,847	165,712	341	166,054
Intersegment	250	585	1	836	2,727	3,564	(3,564)	-
Total	146,178	17,293	1,230	164,701	4,575	169,276	(3,222)	166,054
Segment income (loss)	8,435	1,263	30	9,729	63	9,792	787	10,580

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥45 million and income of the Company not allocated to business segments of ¥742 million.
3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

A ¥247 million impairment loss was recorded in the Takara Bio Group segment with a write-down of the book value of idle assets to the recoverable value.

II. Period under Review (From April 1, 2015, to December 31, 2015)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	146,673	20,048	1,374	168,097	1,807	169,904	346	170,250
Intersegment	185	657	1	845	2,561	3,407	(3,407)	-
Total	146,859	20,706	1,376	168,942	4,369	173,311	(3,061)	170,250
Segment income	8,085	1,444	40	9,570	32	9,603	488	10,091

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥28 million and income of the Company not allocated to business segments of ¥459 million.
3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Changes to Classifications for Reporting Segments)

The Company implemented an absorption-type merger for consolidated subsidiary TaKaRa Network System Co., Ltd. on April 1, 2015. With the merger, the business of TaKaRa Network System, which was included in Other until the previous fiscal year, has been included in Adjustment from the first quarter of this fiscal year.

"Net sales and Income (Loss) by Reported Segment" for the first nine months of the previous fiscal year is presented with amounts reclassified following the relevant changes.

(Application of Revised Accounting Standard for Business Combinations, etc.)

As stated in "Change in Accounting Policy," the "Revised Accounting Standard for Business Combinations" and other standards have been applied from the first quarter of this fiscal year. As a result, for subsidiaries the Company continues to control, differences arising due to changes in the ownership interest are entered in capital

surplus and costs associated with the acquisition of ownership interests are now treated as expenses in the consolidated fiscal year in which they are incurred. In addition, for business combinations that are implemented after the beginning of the first quarter of 2015, revisions to the allocation of the cost of acquisitions as determined by provisional accounting treatment are reflected in the quarterly consolidated financial statements for the quarter in which the business combination took place.

As a result of these changes, segment income for the nine months ended December 31, 2015 increased by ¥26 million for the Takara Shuzo Group as compared with the previous accounting method.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

平成28年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2015

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
   Takara Shuzo Group
   要約損益計算書
   Statements of Income (Summary)

3. タカラバイオグループ
   Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)

4. 平成28年3月期第3四半期　参考資料
   Reference Data for the Third Quarter Ended December 31, 2015

5. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)　→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成27年3月期 第3四半期累計	平成28年3月期 第3四半期累計 Apr. 1, 2015 - Dec. 31, 2015			平成27年3月期 通期	平成28年3月期 通期 Apr. 1, 2015 - Mar. 31, 2016		
	実績(a) FY2015(1Q-3Q) Actual (a)	実績(b) FY2016(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2015 Actual (c)	11/6予想(d) FY2016 Forecast announced Nov. 2015 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
宝酒造 グループ Takara Shuzo Group	146,178	146,859	680	100.5%	190,089	197,500	7,410	103.9%
タカラバイオ グループ Takara Bio Group	17,293	20,706	3,413	119.7%	25,969	＊ 29,000	3,030	111.7%
宝ヘルスケア Takara Healthcare Inc.	1,230	1,376	146	111.9%	1,652	1,900	247	115.0%
その他 Other, net	1,352	1,308	△ 44	96.7%	1,779	1,600	△ 179	89.9%
売上高 Net sales	166,054	170,250	4,196	102.5%	219,490	230,000	10,509	104.8%
売上原価 Cost of sales	100,975	102,349	1,373	101.4%	134,390	139,000	4,609	103.4%
売上総利益 Gross profit	65,078	67,901	2,822	104.3%	85,099	91,000	5,900	106.9%
運送費、保管料 Transportation and storage	6,298	6,574	276	104.4%	8,316	8,800	483	105.8%
広告宣伝費 Advertising	3,050	2,790	△ 260	91.5%	3,656	3,400	△ 256	93.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	23,957	24,561	603	102.5%	32,818	34,000	1,181	103.6%
研究開発費 Research and development	2,485	3,363	878	135.4%	3,754	4,900	1,145	130.5%
管理費、その他 Other, net	18,706	20,519	1,813	109.7%	25,457	28,600	3,142	112.3%
販売費及び一般管理費 SG&A expenses	54,497	57,809	3,311	106.1%	74,003	79,700	5,696	107.7%
宝酒造 グループ Takara Shuzo Group	8,435	8,085	△ 350	95.8%	7,840	8,500	659	108.4%
タカラバイオ グループ Takara Bio Group	1,263	1,444	181	114.4%	2,302	＊ 2,350	47	102.1%
宝ヘルスケア Takara Healthcare Inc.	30	40	10	135.3%	38	60	21	156.9%
その他 Other, net	851	520	△ 330	61.2%	914	390	△ 524	42.6%
営業利益(△:損失) Operating income(Δ:loss)	10,580	10,091	△ 488	95.4%	11,096	11,300	203	101.8%
受取利息・配当金 Interest and Dividends income	572	630	58	110.2%	691	700	8	101.3%
その他営業外収益 Other, net	385	614	229	159.6%	786	700	△ 86	89.0%
営業外収益 Non-operating income	957	1,245	287	130.1%	1,478	1,400	△ 78	94.7%
支払利息 Interest and discounts expenses	347	335	△ 12	96.5%	470	500	29	106.2%
その他営業外費用 Other, net	220	143	△ 77	65.0%	276	200	△ 76	72.4%
営業外費用 Non-operating expenses	568	479	△ 89	84.3%	746	700	△ 46	93.7%
経常利益(△:損失) Ordinary income(Δ:loss)	10,969	10,858	△ 111	99.0%	11,827	12,000	172	101.5%
特別利益 Extraordinary income	312	327	14	104.8%	315	400	84	126.9%
特別損失 Extraordinary loss	529	199	△ 330	37.6%	689	700	10	101.6%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	10,752	10,986	233	102.2%	11,453	11,700	246	102.2%
法人税、住民税及び事業税 Current income taxes	3,578	4,168	589	116.5%	3,858	4,300	△ 788	84.5%
法人税等調整額 Deferred income taxes	1,009	△ 122	△ 1,131	—	1,229			
四半期純利益(△:損失) Net income(Δ:loss)	6,163	6,940	776	112.6%	6,365	7,400	1,034	116.3%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	179	393	213	218.8%	659	1,000	340	151.7%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	5,984	6,546	562	109.4%	5,706	6,400	693	112.2%
設備投資額(有形・無形) Capital expenditures	6,904	3,768	△ 3,135	54.6%	9,533	5,993	△ 3,540	62.9%
減価償却費(有形・無形) Depreciation and Amortization	3,358	3,820	462	113.8%	4,662	4,700	37	100.8%
のれん償却額 Amortization of goodwill	350	404	54	115.6%	500	636	136	127.4%

＊ タカラバイオグループは、平成28年3月期通期業績予想を、1/29に修正しております。(p3参照)
Takara Bio Group revised FY2016 forecasts on January 29, 2016. (c.f. p3.)

営業外収益 Non-operating income	受取利息194、受取配当金436、持分法による投資利益275、補助金収入123 など Interest income 194, Dividends income 436, Equity in earnings of affiliates 275, Subsidy income 123, etc.
営業外費用 Non-operating expenses	支払利息138、社債利息197 など Interest expense 138, Interest on bonds 197, etc.
特別利益 Extraordinary income	投資有価証券売却益260 など Gain on sales of investment securities 260, etc.
特別損失 Extraordinary loss	固定資産除売却損148 など (前期:減損損失247 など) Loss on sales and retirement of noncurrent assets 148, etc. (FY2015(1Q-3Q):Impairment loss 247, etc.)

2. 宝酒造グループ Takara Shuzo Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成27年3月期 第3四半期累計	平成28年3月期 第3四半期累計 Apr. 1, 2015 - Dec. 31, 2015			平成27年3月期 通期	平成28年3月期 通期 Apr. 1, 2015 - Mar. 31, 2016		
	実績(a) FY2015(1Q-3Q) Actual (a)	実績(b) FY2016(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2015 Actual (c)	11/6予想(d) FY2016 Forecast announced Nov. 2015 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
焼酎 Shochu	49,675	45,539	△ 4,135	91.7%	63,583	61,500	△ 2,083	96.7%
清酒 Sake	19,817	19,848	31	100.2%	24,919	27,300	2,380	109.6%
ソフトアルコール飲料 Light-alcohol refreshers	20,249	21,263	1,014	105.0%	25,896	28,200	2,303	108.9%
その他酒類 Other liquors	10,128	10,458	329	103.3%	13,491	14,500	1,008	107.5%
本みりん Hon Mirin	11,368	11,933	564	105.0%	14,570	15,400	829	105.7%
その他調味料 Other seasonings	6,969	7,199	230	103.3%	8,914	9,300	385	104.3%
原料用アルコール等 Raw alcohol	5,378	5,432	54	101.0%	7,437	7,300	△ 137	98.2%
海外日本食材卸 Japanese food wholesale business in overseas markets	12,747	15,164	2,416	119.0%	17,638	20,300	2,661	115.1%
その他 Other	9,843	10,018	175	101.8%	13,635	13,700	64	100.5%
売上高 Net sales	146,178	146,859	680	100.5%	190,089	197,500	7,410	103.9%
売上原価 Cost of sales	91,977	91,986	8	100.0%	120,691	125,000	4,308	103.6%
売上総利益 Gross profit	54,200	54,872	672	101.2%	69,397	72,500	3,102	104.5%
運送費、保管料 Transportation and storage	5,758	6,002	243	104.2%	7,587	8,000	412	105.4%
広告宣伝費 Advertising	2,698	2,382	△ 316	88.3%	3,124	2,900	△ 224	92.8%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	23,258	23,759	500	102.2%	31,818	33,000	1,181	103.7%
研究開発費 Research and development	250	242	△ 8	96.8%	339	400	60	117.7%
管理費、その他 Other, net	13,798	14,400	602	104.4%	18,686	19,700	1,013	105.4%
販売費及び一般管理費 SG&A expenses	45,764	46,787	1,022	102.2%	61,556	64,000	2,443	104.0%
営業利益(△:損失) Operating income(Δ:loss)	8,435	8,085	△ 350	95.8%	7,840	8,500	659	108.4%
営業外収益 Non-operating income	434	580	145	133.4%	596	500	△ 96	83.8%
営業外費用 Non-operating expenses	287	308	21	107.4%	383	400	16	104.4%
経常利益(△:損失) Ordinary income(Δ:loss)	8,583	8,357	△ 226	97.4%	8,054	8,600	545	106.8%
特別利益 Extraordinary income	62	62	0	100.8%	63	200	136	317.0%
特別損失 Extraordinary loss	236	168	△ 68	71.1%	376	300	△ 76	79.8%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	8,409	8,251	△ 157	98.1%	7,741	8,500	758	109.8%
法人税、住民税及び事業税 Current income taxes	2,741	2,616	△ 124	95.4%	2,705	3,100	△ 18	99.4%
法人税等調整額 Deferred income taxes	216	62	△ 153	29.0%	412			
四半期純利益(△:損失) Net income(Δ:loss)	5,450	5,572	121	102.2%	4,623	5,400	776	116.8%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	233	149	△ 83	64.1%	302	400	97	132.2%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	5,217	5,422	205	103.9%	4,320	5,000	679	115.7%
設備投資額(有形・無形) Capital expenditures	3,463	1,783	△ 1,680	51.5%	4,594	2,771	△ 1,823	60.3%
減価償却費(有形・無形) Depreciation and Amortization	2,294	2,396	101	104.4%	3,170	3,000	△ 170	94.6%
のれん償却額 Amortization of goodwill	257	268	11	104.5%	363	456	93	125.7%

3. タカラバイオグループ Takara Bio Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成27年3月期 第3四半期累計	平成28年3月期 第3四半期累計 Apr. 1, 2015 - Dec. 31, 2015			平成27年3月期 通期	平成28年3月期 通期 Apr. 1, 2015 - Mar. 31, 2016		
	実績(a) FY2015(1Q-3Q) Actual (a)	実績(b) FY2016(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2015 Actual (c)	1/29予想(d) FY2016 Forecast announced Jan. 2016 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
研究用試薬 Research reagents	12,021	14,487	2,466	120.5%	17,437	20,401	2,964	117.0%
理化学機器 Scientific instruments	1,700	2,276	576	133.9%	2,705	2,741	36	101.3%
受託・その他 Contracted service and other	1,775	2,114	338	119.1%	3,450	3,643	193	105.6%
バイオ産業支援 計 Bioindustry	15,497	18,878	3,381	121.8%	23,593	26,786	3,193	113.5%
遺伝子医療 Gene Therapy	—	—	—	—	—	—	—	—
医食品バイオ AgriBio	1,796	1,828	32	101.8%	2,376	2,413	36	101.5%
売上高 Net sales	17,293	20,706	3,413	119.7%	25,969	29,200	3,230	112.4%
売上原価 Cost of sales	7,839	9,199	1,359	117.3%	12,142	13,062	920	107.6%
売上総利益 Gross profit	9,453	11,507	2,053	121.7%	13,827	16,137	2,309	116.7%
運送費、保管料 Transportation and storage	453	478	25	105.6%	614	644	30	104.9%
広告宣伝費 Advertising	84	96	12	114.9%	119	126	6	105.7%
販売促進費 Sales promotion	634	732	97	115.4%	903	899	△ 3	99.6%
研究開発費 Research and development	2,225	3,118	893	140.2%	3,401	4,263	862	125.4%
管理費、その他 Other, net	4,792	5,635	843	117.6%	6,486	7,753	1,266	119.5%
販売費及び一般管理費 SG&A expenses	8,190	10,062	1,872	122.9%	11,524	13,687	2,162	118.8%
バイオ産業支援 Bioindustry	3,199	3,938	738	123.1%	5,212	5,967	755	114.5%
遺伝子医療 Gene Therapy	△ 670	△ 1,252	△ 581	—	△ 1,211	△ 1,785	△ 574	—
医食品バイオ AgriBio	△ 147	122	269	—	△ 216	114	331	—
共通 Eliminations/Corporate	△ 1,118	△ 1,363	△ 245	—	△ 1,481	△ 1,846	△ 364	—
営業利益(△:損失) Operating income(Δ:loss)	1,263	1,444	181	114.4%	2,302	2,450	147	106.4%
営業外収益 Non-operating income	158	258	100	163.4%	515	605	89	117.4%
営業外費用 Non-operating expenses	37	5	△ 31	16.0%	45	55	9	120.3%
経常利益(△:損失) Ordinary income(Δ:loss)	1,384	1,697	313	122.6%	2,772	3,000	227	108.2%
特別利益 Extraordinary income	—	4	4	—	0	2	1	275.1%
特別損失 Extraordinary loss	273	28	△ 245	10.3%	292	147	△ 144	50.6%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,110	1,673	563	150.7%	2,481	2,854	373	115.1%
法人税、住民税及び事業税 Current income taxes	726	1,168	441	160.7%	978	1,445	△ 75	95.0%
法人税等調整額 Deferred income taxes	479	△ 112	△ 592	—	543			
四半期純利益(△:損失) Net income(Δ:loss)	△ 95	618	713	—	959	1,409	449	146.9%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	△ 10	4	15	—	△ 4	9	13	—
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	△ 84	613	698	—	963	1,400	436	145.2%
設備投資額(有形・無形) Capital expenditures	3,380	1,850	△ 1,530	54.7%	4,762	2,199	△ 2,563	46.2%
減価償却費(有形・無形) Depreciation and Amortization	956	1,247	290	130.3%	1,347	1,695	348	125.8%
のれん償却額 Amortization of goodwill	92	135	43	146.4%	136	181	44	132.5%

4. 平成28年3月期第3四半期 参考資料 :Reference Data for the Third Quarter Ended December 31, 2015

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成27年3月期 第3四半期累計	平成28年3月期 第3四半期累計 Apr. 1, 2015 - Dec. 31, 2015	
	実績(a) FY2015(1Q-3Q) Actual (a)	実績(b) FY2016(1Q-3Q) Actual (b)	前期差 Change(b-a)
米ドル : US dollar	102.94	120.99	18.05
ポンド: Pound	171.91	185.48	13.57
ユーロ: Euro	139.50	134.75	△ 4.75
人民元: Yuan	16.71	19.33	2.62
100ウォン: 100 Won	9.90	10.78	0.88
インドルピー: Rupee	1.70	1.91	0.21
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	—	14.38	—
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	—	89.20	—

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2015(1Q-3Q)
焼酎 Shochu	22
清酒 Sake	273
ソフトアルコール飲料 Light-alcohol refreshers	2
その他酒類 Other liquors	406
本みりん Hon Mirin	58
その他調味料 Other seasonings	36
原料用アルコール等 Raw alcohol	1
海外日本食材卸 Japanese food wholesale business in overseas markets	△ 98
その他 Other	—
宝酒造グループ 計 Net sales of Takara Shuzo Group	703
研究用試薬 Research reagents	1,207
理化学機器 Scientific instruments	13
受託・その他 Contracted service and other	84
バイオ産業支援 計 Bioindustry	1,306
遺伝子医療 Gene Therapy	—
医食品バイオ AgriBio	—
タカラバイオグループ 計 Net sales of Takara Bio Group	1,306
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	2,009

② 海外売上高比率の推移 :Change in overseas sales ratio

	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)
宝酒造グループ Takara Shuzo Group	4.9%	5.4%	7.9%	12.7%	14.9%
タカラバイオグループ Takara Bio Group	41.3%	41.8%	48.7%	53.1%	56.5%
その他 Other	-	-	-	0.0%	-
宝ホールディングス Takara Holdings Inc. -Consolidated-	8.0%	8.6%	11.9%	16.7%	19.7%

③ 海外主要子会社の業績 :Financial Result of major overseas subsidiaries

		平成27年3月期第3四半期累計実績 FY2015(1Q-3Q) Actual		平成28年3月期 第3四半期累計実績 FY2016(1Q-3Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	20,933	2,676	22,082	2,779
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,154	275	2,671	336
宝酒造食品	千 元 :Thousands of Yuan	36,368	1,969	34,867	1,970
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	607	32	673	38
トマーチン	千 ポ ン ド :Thousands of Pound	12,490	2,437	11,684	2,441
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	2,147	419	2,167	452
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ド ル :Thousands of US dollar	10,187	3,571	10,840	4,040
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	1,048	367	1,311	488
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	65,980	7,754	82,716	8,859
FOODEX Group	百 万 円 :Millions of Yen	9,204	1,081	11,145	1,193
タザキフーズ	千 ポ ン ド :Thousands of Pound	20,797	2,655	21,816	2,026
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	3,575	456	4,046	375
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	10,130	1,050	12,368	1,482
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	1,413	146	1,666	199
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	—	—	22,760	Δ 10,865
Takara Bio Europe AB	百 万 円 :Millions of Yen	—	—	327	Δ 156
宝生物工程(大連)	千 元 :Thousands of Yuan	195,515	74,536	204,956	84,033
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	3,267	1,245	3,961	1,624
宝日医生物技術(北京)	千 元 :Thousands of Yuan	74,926	8,774	70,374	Δ 706
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	1,252	146	1,360	Δ 13
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	5,888	747	6,501	744
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	583	73	700	80
タカラバイオDSSインド	千ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	132,406	Δ 2,122	136,644	4,908
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	225	Δ 3	260	9
タカラバイオUSA	千 US ド ル :Thousands of US dollar	42,671	4,971	51,099	9,730
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	4,392	511	6,182	1,177

④ 宝酒造グループ 営業利益増減要因 :Factors of change in operating income of Takara Shuzo Group

(百万円 :Millions of Yen)

要因 Factors	対前期増減 Change from FY2015(1Q-3Q)	内容 Detail
売上総利益の増減 (宝酒造単体) Change in Gross profit of TAKARA SHUZO CO.,LTD.	Δ 373	数量差 △1,067 単価差 +694 Change in quantities △1,067 Change in unit price +694 ➢主な内訳 Breakdown 焼酎△1,599(数量差△1,458 単価差△140) Shochu △1,599 (Change in quantities △1,458 Change in unit price △140) 清酒△40(数量差△140 単価差+100) Sake △40 (Change in quantities △140 Change in unit price +100) ソフトアルコール飲料+348(数量差+371 単価差△22) Light-alcohol refreshers +348(Change in quantities +371 Change in unit price △22) 本みりん+306(数量差+249 単価差+57) Hon Mirin+306 (Change in quantities +249 Change in unit price +57) (参考)原価コストダウン +594 Reference :Cost reduction +594 ※上記数量差および単価差に含む *Included in changes above
販売費及び一般管理費の増減 (宝酒造単体) Change in SG&A expenses of TAKARA SHUZO CO.,LTD.	Δ 449	運送費の増加 △117 Change in Transportation and storage △117 広告宣伝費の減少 +319 Change in Advertising +319 販売促進費の増加 △525 Change in Sales promotion and allowance for s.p. △525
宝酒造単体 計 TAKARA SHUZO CO.,LTD.	Δ 822	
海外日本食材卸事業の利益増減 Change in Operating income of Japanese food wholesale business in overseas markets	+14	フーデックス +51 Foodex S.A.S. +51 コミンポート +53 Cominport Distribución S.L. +53 タザキフーズ △91 TAZAKI FOODS LTD. △91 ※のれん償却後 *Include amortization of goodwill
その他 Other	+458	タカラ物流システム +197、エイジ・インターナショナル +121 など Takara Butsuryu System Co.,Ltd. +197, AGE INTERNATIONAL,INC. +121, etc.
宝酒造グループ 計 Takara Shuzo Group	Δ 350	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown「+」and「△」, respectively

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	前期対比 Change from FY2015(1Q-3Q) 増減 Change	前期対比 Change from FY2015(1Q-3Q) 比 YOY%
売上高	Net sales	147,969	153,915	155,025	159,519	166,054	170,250	4,196	102.5%
売上原価	Cost of sales	89,423	93,282	94,618	98,027	100,975	102,349	1,373	101.4%
（売上高原価率）	(Ratio to Net sales)	60.4%	60.6%	61.0%	61.5%	60.8%	60.1%	-0.7pt	–
売上総利益	Gross profit	58,545	60,633	60,407	61,491	65,078	67,901	2,822	104.3%
販売費及び一般管理費	SG&A expenses	49,271	50,907	51,246	52,599	54,497	57,809	3,311	106.1%
（売上高販管費率）	(Ratio to Net sales)	33.3%	33.1%	33.1%	33.0%	32.8%	34.0%	+1.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)	9,274	9,725	9,160	8,891	10,580	10,091	Δ 488	95.4%
（売上高営業利益率）	(Ratio to Net Sales)	6.3%	6.3%	5.9%	5.6%	6.4%	5.9%	-0.4pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	22,768	23,723	24,283	24,214	23,957	24,561	603	102.5%
（売上高販促費率）	(Ratio to Net sales)	15.4%	15.4%	15.7%	15.2%	14.4%	14.4%	-0.0pt	–
研究開発費	R&D expenses	2,103	2,169	2,264	2,412	2,485	3,363	878	135.4%
（売上高研究開発費率）	(Ratio to Net sales)	1.4%	1.4%	1.5%	1.5%	1.5%	2.0%	+0.5pt	–
設備投資額（有形・無形）	Capital expenditures	2,422	3,694	4,102	5,324	6,904	3,768	Δ 3,135	54.6%
減価償却費（有形・無形）	Depreciation and Amortization	3,352	3,284	3,132	3,111	3,358	3,820	462	113.8%
のれん償却額	Amortization of goodwill	169	206	201	265	350	404	54	115.6%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	前期対比 Change from FY2015(1Q-3Q) 増減 Change	前期対比 Change from FY2015(1Q-3Q) 比 YOY%
売上高	Net sales	131,604	137,671	138,367	140,850	146,178	146,859	680	100.5%
売上原価	Cost of sales	81,436	85,802	86,994	89,404	91,977	91,986	8	100.0%
（売上高原価率）	(Ratio to Net sales)	61.9%	62.3%	62.9%	63.5%	62.9%	62.6%	-0.3pt	–
売上総利益	Gross profit	50,168	51,868	51,372	51,446	54,200	54,872	672	101.2%
販売費及び一般管理費	SG&A expenses	42,038	43,813	43,789	44,404	45,764	46,787	1,022	102.2%
（売上高販管費率）	(Ratio to Net sales)	31.9%	31.8%	31.6%	31.5%	31.3%	31.9%	+0.6pt	–
営業利益（△：損失）	Operating income(Δ:loss)	8,129	8,055	7,582	7,041	8,435	8,085	Δ 350	95.8%
（売上高営業利益率）	(Ratio to Net sales)	6.2%	5.9%	5.5%	5.0%	5.8%	5.5%	-0.3pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	21,988	22,986	23,542	23,422	23,258	23,759	500	102.2%
（売上高販促費率）	(Ratio to Net sales)	16.7%	16.7%	17.0%	16.6%	15.9%	16.2%	+0.3pt	–
設備投資額（有形・無形）	Capital expenditures	1,634	1,647	1,735	1,969	3,463	1,783	Δ 1,680	51.5%
減価償却費（有形・無形）	Depreciation and Amortization	2,402	2,369	2,205	2,143	2,294	2,396	101	104.4%
のれん償却額	Amortization of goodwill	27	112	110	164	257	268	11	104.5%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	前期対比 Change from FY2015(1Q-3Q) 増減 Change	前期対比 Change from FY2015(1Q-3Q) 比 YOY%
売上高	Net sales	13,035	13,443	13,916	16,167	17,293	20,706	3,413	119.7%
売上原価	Cost of sales	6,090	6,066	6,275	7,500	7,839	9,199	1,359	117.3%
（売上高原価率）	(Ratio to Net sales)	46.7%	45.1%	45.1%	46.4%	45.3%	44.4%	-0.9pt	–
売上総利益	Gross profit	6,945	7,376	7,640	8,666	9,453	11,507	2,053	121.7%
販売費及び一般管理費	SG&A expenses	6,410	6,503	6,932	7,758	8,190	10,062	1,872	122.9%
（売上高販管費率）	(Ratio to Net sales)	49.2%	48.4%	49.8%	48.0%	47.4%	48.6%	+1.2pt	–
営業利益（△：損失）	Operating income(Δ:loss)	535	872	707	908	1,263	1,444	181	114.4%
（売上高営業利益率）	(Ratio to Net sales)	4.1%	6.5%	5.1%	5.6%	7.3%	7.0%	-0.3pt	–
研究開発費	R&D expenses	1,819	1,896	1,993	2,154	2,225	3,118	893	140.2%
（売上高研究開発費率）	(Ratio to Net sales)	14.0%	14.1%	14.3%	13.3%	12.9%	15.1%	+2.2pt	–
設備投資額（有形・無形）	Capital expenditures	721	589	2,058	3,230	3,380	1,850	Δ 1,530	54.7%
減価償却費（有形・無形）	Depreciation and Amortization	841	811	817	849	956	1,247	290	130.3%
のれん償却額	Amortization of goodwill	103	93	90	100	92	135	43	146.4%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	前期対比 Change from FY2015(1Q-3Q) 増減 Change	前期対比 Change from FY2015(1Q-3Q) 比 YOY%
売上高	Net sales	2,052	1,910	1,612	1,027	1,230	1,376	146	111.9%
売上原価	Cost of sales	1,404	1,240	1,013	475	597	650	53	108.9%
（売上高原価率）	(Ratio to Net sales)	68.4%	65.0%	62.9%	46.3%	48.6%	47.3%	-1.3pt	–
売上総利益	Gross profit	647	669	598	551	632	725	93	114.8%
販売費及び一般管理費	SG&A expenses	832	756	621	546	602	685	82	113.7%
（売上高販管費率）	(Ratio to Net sales)	40.5%	39.6%	38.6%	53.2%	49.0%	49.8%	+0.8pt	–
営業利益（△：損失）	Operating income(Δ:loss)	Δ 184	Δ 87	Δ 22	5	30	40	10	135.3%
（売上高営業利益率）	(Ratio to Net sales)	–	–	–	0.5%	2.4%	3.0%	+0.5pt	–
ヘルスケア事業売上高	Net sales of Healthcare products	796	948	931	1,027	1,230	1,376	146	111.9%
設備投資額（有形・無形）	Capital expenditures	–	31	1	2	2	5	2	205.2%
減価償却費（有形・無形）	Depreciation and Amortization	7	8	8	0	1	2	1	244.3%